Browse SORD

Summary
SymbolSORD
Namesorbitol dehydrogenase
Aliases HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location15q15-q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion membrane Peripheral membrane protein Cell projection, cilium, flagellum Note=Associated with mitochondria of the midpiece and near the plasma membrane in the principal piece of the flagellum. Also found in the epididymosome, secreted by the epididymal epithelium and that transfers proteins from the epididymal fluid to the sperm surface.
Domain PF08240 Alcohol dehydrogenase GroES-like domain
PF00107 Zinc-binding dehydrogenase
Function

Converts sorbitol to fructose. Part of the polyol pathway that plays an important role in sperm physiology. May play a role in the sperm motility by providing an energetic source for sperm.

> Gene Ontology
 
Biological Process GO:0005996 monosaccharide metabolic process
GO:0006000 fructose metabolic process
GO:0006006 glucose metabolic process
GO:0006059 hexitol metabolic process
GO:0006060 sorbitol metabolic process
GO:0006062 sorbitol catabolic process
GO:0006063 uronic acid metabolic process
GO:0006064 glucuronate catabolic process
GO:0006066 alcohol metabolic process
GO:0006970 response to osmotic stress
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0016051 carbohydrate biosynthetic process
GO:0016052 carbohydrate catabolic process
GO:0016054 organic acid catabolic process
GO:0019318 hexose metabolic process
GO:0019319 hexose biosynthetic process
GO:0019400 alditol metabolic process
GO:0019405 alditol catabolic process
GO:0019407 hexitol catabolic process
GO:0019519 pentitol metabolic process
GO:0019527 pentitol catabolic process
GO:0019585 glucuronate metabolic process
GO:0019640 glucuronate catabolic process to xylulose 5-phosphate
GO:0019751 polyol metabolic process
GO:0030317 flagellated sperm motility
GO:0031667 response to nutrient levels
GO:0042493 response to drug
GO:0044262 cellular carbohydrate metabolic process
GO:0044275 cellular carbohydrate catabolic process
GO:0044282 small molecule catabolic process
GO:0044283 small molecule biosynthetic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044724 single-organism carbohydrate catabolic process
GO:0046164 alcohol catabolic process
GO:0046174 polyol catabolic process
GO:0046364 monosaccharide biosynthetic process
GO:0046370 fructose biosynthetic process
GO:0046395 carboxylic acid catabolic process
GO:0046686 response to cadmium ion
GO:0046688 response to copper ion
GO:0051160 L-xylitol catabolic process
GO:0051164 L-xylitol metabolic process
GO:0051167 xylulose 5-phosphate metabolic process
GO:0072329 monocarboxylic acid catabolic process
GO:0097722 sperm motility
GO:1901159 xylulose 5-phosphate biosynthetic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901616 organic hydroxy compound catabolic process
GO:1990267 response to transition metal nanoparticle
Molecular Function GO:0003939 L-iditol 2-dehydrogenase activity
GO:0016614 oxidoreductase activity, acting on CH-OH group of donors
GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0030246 carbohydrate binding
GO:0031320 hexitol dehydrogenase activity
GO:0046526 D-xylulose reductase activity
GO:0048037 cofactor binding
GO:0050662 coenzyme binding
GO:0051287 NAD binding
Cellular Component GO:0005929 cilium
GO:0031514 motile cilium
> KEGG and Reactome Pathway
 
KEGG hsa00040 Pentose and glucuronate interconversions
hsa00051 Fructose and mannose metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-5661270: Catabolism of glucuronate to xylulose-5-phosphate
R-HSA-5652227: Fructose biosynthesis
R-HSA-5652084: Fructose metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolSORD
Namesorbitol dehydrogenase
Aliases HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location15q15-q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SORD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSORD
Namesorbitol dehydrogenase
Aliases HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location15q15-q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SORD in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSORD
Namesorbitol dehydrogenase
Aliases HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location15q15-q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SORD in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.7280.0337
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4990.796
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.890.554
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4260.342
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3120.847
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5780.751
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1130.783
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1030.948
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0110.995
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1250.924
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.30.881
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1230.391
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SORD in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSORD
Namesorbitol dehydrogenase
Aliases HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location15q15-q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SORD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSORD
Namesorbitol dehydrogenase
Aliases HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location15q15-q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SORD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SORD.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSORD
Namesorbitol dehydrogenase
Aliases HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location15q15-q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SORD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSORD
Namesorbitol dehydrogenase
Aliases HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location15q15-q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SORD expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSORD
Namesorbitol dehydrogenase
Aliases HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location15q15-q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SORD and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSORD
Namesorbitol dehydrogenase
Aliases HEL-S-95n1; L-iditol 2-dehydrogenase; epididymis secretory sperm binding protein Li 95n
Chromosomal Location15q15-q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SORD collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SORD.
ID Name Drug Type Targets #Targets
DB00157NADHSmall MoleculeAASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......144
DB04478Cp-166572, 2-Hydroxymethyl-4-(4-N,N-Dimethylaminosulfonyl-1-Piperazino)-PyrimidineSmall MoleculeSORD1